CNCR CNCR

Loncar Cancer Immunother... Share Price

19.50
0.00 (0.0%)
19.50
Volume 0
Bid Price 16.42
Ask Price 23.94
News -
Day High

Low
19.50

52 Week Range

High
35.818

Day Low
Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
$52.04
Small Cap Basic
Monthly Subscription
for only
$33.03
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
$67.09
VAT not included
Company Name Etf Ticker Symbol Market Type
Loncar Cancer Immunotherapy CNCR NASDAQ Exchange Traded Fund
  Price Change Change Percent Etf Price Last Traded
0.00 0.0% 19.50 04:00:00
Open Price Low Price High Price Close Price Prev Close
19.50
Last Trade Time Type Quantity Etf Price Currency
- 0  19.50 USD

Period:

Draw Mode:

Loncar Cancer Immunotherapy Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
 26.33M 1.35M 1.35M  -  - - -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
-  - 9.50% 12/29/21 - -

more financials information »

News Loncar Cancer Immunother...

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

CNCR Historical

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week20.4120.6919.5019.9729,393-0.91-4.46%
1 Month26.4426.64519.5021.3011,176-6.94-26.25%
3 Months28.9330.4919.5024.236,777-9.43-32.6%
6 Months30.3431.7019.5026.935,860-10.84-35.73%
1 Year35.0035.81819.5029.236,241-15.50-44.29%
3 Years20.8135.81812.0024.9010,032-1.31-6.3%
5 Years21.3535.81812.0025.0815,202-1.85-8.67%

The investment seeks to track the total return performance, before fees and expenses, of the Loncar Cancer Immunotherapy Index. The index is composed of the common stock of approximately 30 pharmaceutical or biotechnology companies identified by the fund's index provider, as having a high strategic focus on the development of drugs that harness the body's own immune system to fight cancer. The adviser attempts to invest all, or substantially all, of its assets in the component securities and ADRs that make up the index. At least 80% of its total assets will be invested in the component securities of the index. The fund is non-diversified.


Your Recent History
NASDAQ
CNCR
Loncar Can..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.